ABCL
AbCellera Biologics Inc.
AbCellera Biologics (ABCL) Q2 2026 earnings
Published Aug 5, 2026
AI summary
- Revenue $4.05M, down 76% from $17.1M a year ago.
- GAAP EPS −$0.18 missed the −$0.17 consensus by $0.01, down from −$0.12 a year ago.
- AbCellera reported second quarter 2026 revenue of $4.1 million, down from $17.1 million in the prior year period.
- The company recorded a net loss of $55.4 million for the quarter, compared to a $34.7 million loss in Q2 2025.
- New collaborations with Jazz Pharmaceuticals and Vertex Pharmaceuticals were announced to advance T-cell engager programs.
Results vs analyst consensus
Revenue
Reported
$4.05M
Consensus not captured before release
−76% YoY
EPS · GAAP (street basis)
Reported · Diluted EPS (GAAP, street basis)
−$0.18
Consensus −$0.17
Missed by $0.01GAAP EPS: −$0.18
Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The number of partner-led programs held by the company decreased from 44 at the end of 2025 to 35 as of June 30, 2026.
Read original report
Source: AbCellera Biologics Inc. press release · SEC Form 8-K exhibit 99.1